Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/MPH.0000000000003140 http://scihub22266oqcxt.onion/10.1097/MPH.0000000000003140 41359882!?!41359882       J+Pediatr+Hematol+Oncol 2025 ; ? (?): ? Nephropedia Template TP {{tp|p=41359882|t=2025. Navigating Management of Spindle Cell/Sclerosing Rhabdomyosarcoma With FUS::TFCP2 Fusion in the Era of Targeted Therapy |pdf=|usr=}}{{41359882}} gab.com Text Navigating Management of Spindle Cell/Sclerosing Rhabdomyosarcoma With FUS::TFCP2 Fusion in the Era of Targeted Therapy JO: J Pediatr Hematol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=41359882 #FOAvip Spindle cell/sclerosing rhabdomyosarcoma (ssRMS) with FUS-TFCP2 translocation is a rare, aggressive RMS subtype often involving facial and pelvic bones and showing poor response to standard therapy. The FUS-TFCP2 fusion drives ALK gene activation and overexpression, suggesting ALK as a therapeutic target, though clinical use of ALK inhibitors remains limited in this context. We report a case of mandibular ssRMS with FUS-TFCP2 fusion treated with the third-generation ALK inhibitor Lorlatinib, resulting in a marked clinical response. We also review the potential utility of ALK-targeted therapies in managing FUS-TFCP2 fusion-positive ssRMS and support further exploration of ALK inhibition in this subset. Twit Text FOAVip Navigating Management of Spindle Cell/Sclerosing Rhabdomyosarcoma With FUS::TFCP2 Fusion in the Era of Targeted Therapy ????J Pediatr Hematol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=41359882 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=41359882 #FOAvip English Wikipedia <ref>{{Cite pmid|41359882}}</ref> Navigating Management of Spindle Cell/Sclerosing Rhabdomyosarcoma With FUS::TFCP2 Fusion in the Era of Targeted Therapy #MMPMID41359882 Okeleji O; Raj R; Farha S; Ehab H; Paulino AC; Salvador L; Choi J; Williams M; Harrison D J Pediatr Hematol Oncol 2025[Nov]; ? (?): ? PMID41359882show ga Spindle cell/sclerosing rhabdomyosarcoma (ssRMS) with FUS-TFCP2 translocation is a rare, aggressive RMS subtype often involving facial and pelvic bones and showing poor response to standard therapy. The FUS-TFCP2 fusion drives ALK gene activation and overexpression, suggesting ALK as a therapeutic target, though clinical use of ALK inhibitors remains limited in this context. We report a case of mandibular ssRMS with FUS-TFCP2 fusion treated with the third-generation ALK inhibitor Lorlatinib, resulting in a marked clinical response. We also review the potential utility of ALK-targeted therapies in managing FUS-TFCP2 fusion-positive ssRMS and support further exploration of ALK inhibition in this subset. ?Navigating Management of Spindle Cell/Sclerosing Rhabdomyosarcoma With(epmc).pdf DeepDyve Pubget Overpricing